Sanofi Genzyme
Industry / private company
Location:
Cambridge, MA,
United States (USA) (US)
ISNI: 0000 0004 6024 9625
Burden of illness of Fabry disease: A retrospective claims analysis of a German sickness fund database (2021)
Hilz MJ, Marczykowski F, Lyn N, Werner B, Pignot M, Ponce E, Bender J, et al.
Conference contribution
A cell-based drug delivery platform for treating central nervous system inflammation. (2021)
Levy O, Rothhammer V, Mascanfroni I, Tong Z, Kuai R, De Biasio M, Wang Q, et al.
Journal article
EVALUATION OF TREATMENT PATTERNS OF FABRY DISEASE UTILIZING MEDICAL CLAIMS ANALYSES OF A GERMAN SICKNESS FUND DATABASE (2020)
Hilz MJ, Dasmahapatra P, Fan Q, Marczykowski F, Werner B, Pignot M, Bender J, et al.
Conference contribution
FOSL-2 IS A REPRESSOR OF FOXP3 EXPRESSION DURING TREG DEVELOPMENT AND CONTROLS AUTOIMMUNITY (2019)
Renoux F, Stellato M, Vogetseder A, Huang R, Subramaniam A, Blyszczuk P, Distler J, et al.
Conference contribution
FRA2 OVEREXPRESSION LEADS TO SYSTEMIC AUTOIMMUNITY BY DECREASING IL-2 RESPONSIVENESS AND THYMIC TREG DEVELOPMENT (2017)
Renoux F, Stellato M, Impellizzieri D, Vogetseder A, Huang R, Subramaniam A, Dees C, et al.
Conference contribution
Fra-2 Overexpression Leads to Systemic Autoimmunity By Affecting IL2 Dependent Treg Homeostasis (2017)
Renoux F, Stellato M, Impellizzieri D, Vogetseder A, Blyszczuk P, Huang R, Subramaniam A, et al.
Conference contribution